申请人:Institute Of Pharmacology And Toxicology Academy
Of Military Medical Sciences P.L.A. China
公开号:EP2354136A1
公开(公告)日:2011-08-10
The invention discloses novel piperazine derivatives represented by formula I having activity for modulating dopamine D3 receptor, their stereoisomers, pharmaceutical salts, solvates, and the pharmaceutical compositions containing such compounds, their preparation and the use of such compounds for preventing or treating the diseases correlated with central nervous system disorder, such as Parkinson's disease, schizophrenia, drug addiction and relapse and the like, as well as the use of such compounds for kidney protection and immune modulation, or as implemental medicine for researching the function of D3R and the diseases correlated with disorder of D3R function.
本发明公开了具有调节多巴胺 D3 受体活性的式 I 所代表的新型哌嗪衍生物、它们的立体异构体、药用盐、溶解物以及含有此类化合物的药物组合物、它们的制备方法以及此类化合物在预防或治疗与中枢神经系统紊乱有关的疾病方面的用途、如帕金森病、精神分裂症、药物成瘾和复发等,以及将此类化合物用于肾脏保护和免疫调节,或作为研究 D3R 功能和与 D3R 功能紊乱相关疾病的实施药物。